Thrombolytic therapy in cerebrovascular disorders

Area of Science:

• Neurology
• Cardiovascular Research
• Emergency Medicine

Background:

• Acute ischemic stroke requires rapid intervention to minimize brain damage.
• Experimental models demonstrate a critical time window for effective treatment, typically within a few hours of occlusion.
• Spontaneous reperfusion in patients often occurs too late for significant benefit.

Purpose of the Study:

• To evaluate the effectiveness of tissue plasminogen activator (tPA) in acute ischemic stroke.
• To establish optimal dosage ranges and complication rates for tPA therapy.
• To emphasize the necessity of a rapid, aggressive team approach for successful acute stroke treatment.

Main Methods:

• Review of ongoing investigational trials of tPA for acute ischemic stroke.
• Analysis of experimental cerebral ischemia data from animal models (dogs, cats, primates).
• Synthesis of factors influencing successful outcomes in thrombolytic therapy.

Main Results:

• Experimental data suggest salvage of ischemic brain is unlikely if occlusion persists beyond 4-6 hours.
• Complete recovery in animal models is associated with occlusion durations of less than 2 hours.
• Early clinical trials with thrombolytic agents face challenges, with potential for tPA in specific thromboembolic strokes.

Conclusions:

• tPA may be valuable for certain thromboembolic strokes, dependent on rapid initiation and risk assessment.
• Current tPA doses might be insufficient for large cerebral clots, necessitating further trials with higher doses.
• Acute stroke must be recognized as a medical emergency, akin to myocardial infarction and trauma, requiring immediate, coordinated care.